课题基金 / 基金详情

Development and clinical application of the molecular diagnostic tests for individualization of cancer chemotherapy: detection of gene polymorphism of metabolizing enzyme and expression pattern

Development and clinical application of the molecular diagnostic tests for individualization of cancer chemotherapy: detection of gene polymorphism of metabolizing enzyme and expression pattern
癌症化疗个体化分子诊断检测的开发及临床应用:代谢酶基因多态性及表达模式检测
批准号:
12672254
负责人:
MIYACHI Hayato
金额:
$1.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

MIYACHI Hayato的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Drug resistance is a major obstacle in chemotherapy of leukemia patients. Since the treatment responsiveness is different among patients, the therapy should be tailored to specific subtypes of diseases such as defined by drug resistance. To elucidate mechanism(s) of methotrexate (MTX)-resistance as a possible reason behind treatment failure in high-dose MTX regimens combined with leucovorin (LV) rescue, we established MTX-resistant human T-cell leukemia cell line CCRF-CEM cells in the presence of excessive leucovorin, and characterized their property. Continuous exposure of the cells to escalating concentrations of MTX up to 20μM in the presence of 1000 nM leucovorin resulted in establishment of three MTX-resistant sublines with a wide disparity of resistance degree over 4 logarithmic range by approximately 40-, 900- and 44000-fold, respectively. Transraembrane transport of MTX in these sublines was diminished to 52%, 35% and 12%, respectively. Intracellular retention of MTX in these s … More ublines was not different from the parent cells. A cell growth study in various concentrations of leucovorin showed that cells with higher resistance to MTX required more leucovorin supply for their optimal growth. In parallel with the resistance levels, there was increase in mRNA expression of dihydrofolate reductase gene and decrease in that of thymidylate synthase gene, but no change in that of reduced folate carrier (RFC1) gene, as assessed by northern blot analysis. Sequencing of RFC1 gene in all of the 3 sublines revealed a point mutation in codon 47 (TCC→TTC) resulting in substitution of Phe for Ser residue, and additional deletion of CTG of codon 112 in the subline with the highest resistance. In summary, MTX exposure to CCRF-CEM cells in the presence of 1000 nM leucovorin resulted in an establishment of heterogeneous cell populations with a wide range of transport-mediated MTX-resistance, which was associated with differential alterations of RFC gene. Combination of gene expression and mutations involved in the molecular mechanisms of MTX-resistance may give targets for detection and evaluation of it. Less
期刊论文(32)
专著(0)
科研奖励(0)
会议论文
Efeerth T, Dunstan H, Sauerbrey A, Miyachi H, et al.: "The anti-malarial artesunate is also active against cancer"Intern J Oncol.. 18. 767-773 (2001)
Efeerth T、Dunstan H、Sauerbrey A、Miyachi H 等人:“抗疟疾青蒿素对癌症也有活性”Intern J Oncol.. 18. 767-773 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
宮地勇人, 他: "癌の薬剤耐性とその克服-基礎と臨床-"宇宙堂. 41 (2001)
Hayato Miyaji 等人:“癌症耐药性及其克服 - 基础知识和临床实践”Uchudo 41 (2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kobayashi H, Takemura Y, Miyachi H: "Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics"Human Cell. 14. 172-181 (2001)
Kobayashi H、Takemura Y、Miyachi H:“利用基因特异性疗法逆转抗癌药物耐药性的新方法”《人类细胞》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
宮地勇人, 他: "cDNAマイクロアレイ技術の臨床検査への応用.遺伝子発現プロファイル解析による癌の薬剤耐性形質の評価"臨床病理. 50. 161-168 (2002)
Hayato Miyaji 等人:“cDNA 微阵列技术在临床测试中的应用。通过基因表达谱分析评估癌症的耐药性特征”《临床病理学》50. 161-168 (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
21
    Development of an evaluation method based on the elucidation of drug-resistance mechanisms of leukaemia cells through bone marrow niche cross talk
    • 批准号:
      18K07425
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2018
    • 负责人:
      MIYACHI Hayato
    • 依托单位:
    Molecular mechanisms of refractory leukemia cells in the bone marrow microenvironment
    • 批准号:
      15K08654
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2015
    • 负责人:
      MIYACHI Hayato
    • 依托单位:
    Elucidation of Molecular Mechanisms of Refractory Leukemia: Diagnostic Implications of FLT3-ITD Associated Biomarkers for Drug Resistance.
    • 批准号:
      24590709
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.49万
    • 财政年份:
      2012
    • 负责人:
      MIYACHI Hayato
    • 依托单位:
    Elucidation of molecular mechanisms of drug-resistant leukemia through micro RNA analysis : applications to laboratory diagnostics
    • 批准号:
      21590640
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      MIYACHI Hayato
    • 依托单位:
    海外基金